The study, published July 14 in Critical Care Explorations, found that Cytovale’s IntelliSep Index sepsis test was also cheaper than alternative solutions, at just $3,849 per patient as opposed to the widely-available, alternative procalcitonin sepsis test’s 94 percent survival rate and cost of $4,656 per patient.
“For patients who have sepsis, getting sent home from the hospital is very serious because they can suffer multiple-organ failure within hours,” Christopher Hollenbeak, PhD, study lead and a professor of health policy and administration at the Penn State College of Health and Human Development stated in a Sept. 25 news release. “Every year, there are patients who enter the emergency department of a hospital, present with a limited number of sepsis symptoms and are sent home. This test could save many of those people’s lives.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
